Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03634436 at ClinicalTrials.govnct03944109 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
nct05370950 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
nct04455581 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
nct04849000 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
nct04885218 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
nct04844125 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
Documents that mention this clinical trial
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
https://doi.org/10.1007/s40262-025-01512-5
- License Information
-
More Information
Article History
Accepted: 17 April 2025
First Online: 30 June 2025
Declarations
:
: Jiangsu Hengrui Pharmaceuticals.
: Chang S, Ying W, Sheng F, Shengxian Y, Kai S were all employed by Jiangsu Hengrui Pharmaceuticals. All authors declare that there are no conflicts of interest.
: Informed consent was obtained from all individual participants included in the studies. No identifying information for individual patients is included in this article.
: Not available.
: Not available.
: The individual patient data generated during this study will be considered for sharing after the product and indications have been approved by major health authorities. The data may be requested 24 months after study completion. Qualified researchers should submit a proposal to the corresponding author outlining the reasons for the data request. The sponsor will provide the data if the proposal is approved, provided that the requestor signs a data-access agreement. The use of data must comply with the requirements of the Human Genetics Resources Administration of China and other country- or region-specific regulations.
: Not available.
: Chang S was responsible for drafting the analysis plan, verifying the dataset, conducting modeling and analysis, and drafting the manuscript. Ying W was in charge of clinical pharmacology of recaticimab and was accountable for materials collection; Shengxian Y programmed the dataset; the project was under supervised by Sheng F and Kai S.
